Company: GHRS
Filing Date: 2025-02-27
Form Type: 20-F
Source: 0001140361-25-006175
Chunk: 0

Company: GH Research PLC
Filing Date: 2025-02-27
Form: 20-F
Item: Item 11
Chunk 0
---
our” refer to (i) GH Research Ireland Limited prior to the completion of our corporate reorganization in connection with our initial public offering, or the Corporate Reorganization and (ii) GH Research PLC (and, where the context requires, its subsidiary) following the completion of the Corporate Reorganization. For information on our Corporate Reorganization, see Exhibit 2.1 to this Annual Report.
Financial Statements
 
Our financial information is presented in U.S. dollars. We prepare our consolidated financial statements in accordance with the IFRS Accounting Standards as adopted by the International Accounting Standards Board (IASB). The terms “dollar,” “USD” or “$” refer to U.S. dollars and all references to “€” are to euro.
Market and Industry Data
 
This Annual Report contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research. Third-party publications, surveys and studies generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. These data involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty. We caution you not to give undue weight to such projections, assumptions or estimates.
Rounding
 
We have made rounding adjustments to some of the figures included in this Annual Report. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
 
This Annual Report contains statements that are, or may be deemed to be, forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Section 27A of the Securities Act of 1933, as amended, or the Securities Act. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, product candidates, medical devices required to deliver these product candidates, research pipeline, ongoing and planned nonclinical studies and clinical trials, regulatory submissions and approvals and their effects on our business strategy, including our plans and expectations for discussions with the U.S. Food and Drug Administration, or the FDA, and the outcomes and resolution of such discussions related to the clinical hold on the GH001 investigational